Regulus Therapeutics Inc logo

Regulus Therapeutics Inc

NEW
NAS:RGLS (USA)  
$ 1.29 -0.010 (-0.77%) 10:20 AM EST
At Loss
P/B:
1.10
Market Cap:
$ 85.45M
Enterprise V:
$ 9.96M
Volume:
36.60K
Avg Vol (2M):
550.38K
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
36.60K
At Loss
Avg Vol (2M):
550.38K

Business Description

Description
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Name Current Vs Industry Vs History
Cash-To-Debt 276.56
Equity-to-Asset 0.91
Debt-to-EBITDA -0.01
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 10.98
Quick Ratio 10.98
Cash Ratio 10.1

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -64.9
Shareholder Yield % -102.88

Financials (Next Earnings Date:2025-05-09 Est.)

RGLS's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:RGLS

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Regulus Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -0.87
Beta 0.92
3-Year Sharpe Ratio 0.16
3-Year Sortino Ratio 0.3
Volatility % 118.05
14-Day RSI 47.12
14-Day ATR ($) 0.117972
20-Day SMA ($) 1.3615
12-1 Month Momentum % -54.96
52-Week Range ($) 0.8301 - 3
Shares Outstanding (Mil) 66.24

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Regulus Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Regulus Therapeutics Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Regulus Therapeutics Inc Frequently Asked Questions

What is Regulus Therapeutics Inc(RGLS)'s stock price today?
The current price of RGLS is $1.29. The 52 week high of RGLS is $3.00 and 52 week low is $0.83.
When is next earnings date of Regulus Therapeutics Inc(RGLS)?
The next earnings date of Regulus Therapeutics Inc(RGLS) is 2025-05-09 Est..
Does Regulus Therapeutics Inc(RGLS) pay dividends? If so, how much?
Regulus Therapeutics Inc(RGLS) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1